Last reviewed · How we verify

Switch to TDF/FTC/RPV after 24 weeks — Competitive Intelligence Brief

Switch to TDF/FTC/RPV after 24 weeks (Switch to TDF/FTC/RPV after 24 weeks) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + NNRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Switch to TDF/FTC/RPV after 24 weeks (Switch to TDF/FTC/RPV after 24 weeks) — Azienda Ospedaliera San Gerardo di Monza. A combination antiretroviral regimen that suppresses HIV replication by inhibiting reverse transcriptase and integrase through three complementary agents.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Switch to TDF/FTC/RPV after 24 weeks TARGET Switch to TDF/FTC/RPV after 24 weeks Azienda Ospedaliera San Gerardo di Monza marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase
3TC 3TC Avexa marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase; hepatitis B polymerase
Lamivudine (LAM) Lamivudine (LAM) Hoffmann-La Roche marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase; Hepatitis B virus reverse transcriptase
tenofovir disproxil fumarate/emtricitabine tenofovir disproxil fumarate/emtricitabine Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections marketed Nucleoside/nucleotide reverse transcriptase inhibitor combination HIV reverse transcriptase
Lamiduvine (Epivir) Lamiduvine (Epivir) Catholic University of the Sacred Heart marketed Nucleoside Reverse Transcriptase Inhibitor (NRTI) HIV reverse transcriptase
Truvada Pill Truvada Pill University of North Carolina, Chapel Hill marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase
Doravirine + tenofovir DF + lamivudine Doravirine + tenofovir DF + lamivudine Instituto Mexicano del Seguro Social marketed Antiretroviral combination (NNRTI + NRTIs) HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + NNRTI) class)

  1. GlaxoSmithKline · 2 drugs in this class
  2. Clinical Trial Agency of HIV Study Group · 1 drug in this class
  3. Hospital Clinic of Barcelona · 1 drug in this class
  4. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · 1 drug in this class
  5. National Center for AIDS/STD Control and Prevention, China CDC · 1 drug in this class
  6. Peking Union Medical College Hospital · 1 drug in this class
  7. Sheba Medical Center · 1 drug in this class
  8. Azienda Ospedaliera San Gerardo di Monza · 1 drug in this class
  9. University of KwaZulu · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Switch to TDF/FTC/RPV after 24 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/switch-to-tdf-ftc-rpv-after-24-weeks. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: